InvestorsHub Logo
Followers 43
Posts 9124
Boards Moderated 0
Alias Born 01/06/2011

Re: Whalatane post# 36957

Monday, 10/20/2014 6:54:31 PM

Monday, October 20, 2014 6:54:31 PM

Post# of 429056
That is wishful thinking, but they can not plan on a maybe. Taking the conservative approach to sales will take to long, I think they need to expand their Marketing/Sales force, perhaps even change the current method of marketing. The one they are using just is not working well. In other words we need a new marketing strategy.

I have seen T.V. Ads for drugs recently approved! Do we have any?
I think making patients aware of a drug like ours, will work. Patients can have an effect on physicians. I know I did, and many others here have had the same experience!

Regarding insurance coverage, just because STS66 insurance coverage move to a higher tier is meaningless, more insurance companies have moved to tier two, and no special requirement.

I hope we see an early completion on RI results, it may happen. But lets say by mid 2016 we are looking at minimal sales, no indication that REDUCE-IT is being stopped. Since we marketed Vascepa for a small market share, the market you suggest they focus on, will lead to small script numbers, low income, low PPS!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News